Aspirin and the Primary Prevention of Cardiovascular Diseases. An Approach Based on Individualized, Integrated Estimation of Risk by Volpe, Massimo et al.
High Blood Pressure & Cardiovascular Prevention
 
Aspirin and the primary prevention of cardiovascular diseases:  An approach based on
individualized, integrated estimation of risk
--Manuscript Draft--
 
Manuscript Number: BPCP-D-17-00011
Full Title: Aspirin and the primary prevention of cardiovascular diseases:  An approach based on
individualized, integrated estimation of risk
Article Type: Position paper
Funding Information:
Abstract: While the use of aspirin in the secondary prevention of cardiovascular (CVD) is well
established, aspirin in primary prevention is not systematically recommended because
the absolute CV event reduction is similar to the absolute excess in major bleedings.
Recently, emerging evidence suggest the possibility that the assumption of aspirin,
may also be effective in the prevention of cancer. By adding to the CV prevention
benefits, the potential beneficial effect of aspirin in reducing the incidence of mortality
and cancer could tip the balance between risks and benefits of aspirin therapy in the
primary prevention in favour of the latter and broaden the indication for treatment with
in populations at average risk.
While prospective and randomized study are currently investigating the effect of aspirin
in prevention of both cancer and CVD, clinical efforts at the individual level to promote
the use of aspirin in global (or total) primary prevention could be already based on a
balanced evaluation of the benefit/risk ratio.
Corresponding Author: Massimo Volpe, Prof.
University of Rome Sapienza
Rome, ITALY
Corresponding Author Secondary
Information:
Corresponding Author's Institution: University of Rome Sapienza
Corresponding Author's Secondary
Institution:
First Author: Massimo Volpe, Prof.
First Author Secondary Information:
Order of Authors: Massimo Volpe, Prof.
Allegra Battistoni
Giovanna Gallo
Roberta Coluccia
Raffaele De Caterina
Order of Authors Secondary Information:
Author Comments: Dear Editor,
Enclosed please find our manuscript, entitled "Aspirin and the primary prevention of
cardiovascular diseases:  an approach based on individualized, integrated estimation
of risk.", that we wish to submit for evaluation and potential publication on High Blood
Pressure and Cardiovascular Prevention.
As you will see, this manuscript addresses in a critical way evidence published so far
about the favourable effect of the treatment with aspirin in subjects without previous
known cardiovascular diseases. In our opinion, this is a topic of growing importance
and interest, as recent data, derived from longer follow up of previous randomized
controlled trial and from meta-analysis, may account for an enlarged indication for
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
therapy with aspirin in primary prevention.
In particular, Authors decided to propose a global estimation of individual risk, by
focusing on the comparative evaluation of the anti atherotrombotic, antineoplastic
actions of aspirin and the consequent increased risk of bleeding. We strongly believe
that this "state of the art" paper could be helpful to clinicians in everyday practice.
Please consider that the paper in the present version is not under consideration
elsewhere.
A recent Italian consensus document of the Italian Society of Cardiovascular
Prevention (SIPREC) reports many of the concepts reported in the present position
article. Therefore, we acknowledge the contribution of Prof. Carlo Patrono and Prof.
Bruno Trimarco to have critically gone through the Italian version of this manuscript.
All of the authors have read and approved the manuscript.
I sincerely hope you will find our manuscript of interest for the Readers of High Blood
Pressure and Cardiovascular Prevention and I wish to thank you in advance for the
consideration you will give to our work.
With my best regards,
Massimo Volpe
Suggested Reviewers: claudio Ferri
claudio.ferri@cc.univaq.it
Expert in the field of CV prevention
claudio borghi
claudio.borghi@unibo.it
expert in the filed of CV prevention
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
1 
 
Aspirin and the primary prevention of cardiovascular diseases:  
An approach based on individualized, integrated estimation of risk 
 
Massimo Volpe1-2, Allegra Battistoni1, Giovanna Gallo1, Roberta Coluccia2, Raffaele De 
Caterina3 
1 Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of 
Medicine and Psychology, University of Rome Sapienza, Sant’Andrea Hospital, Rome, 
Italy; 2 IRCCS Neuromed, Pozzilli (IS), Italy; 3 Institute and Chair of Cardiology G. 
d’Annunzio University - Chieti-Pescara C/o Ospedale SS. Annunziata 
 
ORCID number: MV 0000-0002-9642-8380; RDC 0000-0003-1637-574X 
 
Address for Correspondence: Prof. Massimo Volpe, MD, FAHA, FESC, Division of 
Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and 
Psychology, University of Rome Sapienza, Sant’Andrea Hospital, Rome, Italy; Phone: +39 
06 3377 5654; Fax: +39 06 3377 6323; e-mail: massimo.volpe@uniroma1.it 
 
Total word count: 4248 
Keywords: aspirin, cardiovascular risk, primary prevention, cancer 
 
 
 
 
 
 
 
 
Manuscript Click here to download Manuscript ASA_EN_1902.doc 
Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
2 
 
Abstract (161 words) 
While the use of aspirin in the secondary prevention of cardiovascular (CVD) is well 
established, aspirin in primary prevention is not systematically recommended because the 
absolute CV event reduction is similar to the absolute excess in major bleedings. Recently, 
emerging evidence suggest the possibility that the assumption of aspirin, may also be 
effective in the prevention of cancer. By adding to the CV prevention benefits, the potential 
beneficial effect of aspirin in reducing the incidence of mortality and cancer could tip the 
balance between risks and benefits of aspirin therapy in the primary prevention in favour of 
the latter and broaden the indication for treatment with in populations at average risk.  
While prospective and randomized study are currently investigating the effect of aspirin in 
prevention of both cancer and CVD, clinical efforts at the individual level to promote the 
use of aspirin in global (or total) primary prevention could be already based on a balanced 
evaluation of the benefit/risk ratio. 
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Introduction 
The twentieth Century may be characterized, from the standpoint of Medicine, as the 
“Century of Aspirin”, since acetylsalicylic acid, aspirin, has been one of the most 
outstanding medical innovations, which has improved, without any doubt, the expectancy 
and the quality of life for many people across the world. In “The Revolt of the Masses”, J. 
O. Gasset wrote: “The life of the average man today is easier, more convenient and safer 
than that of the most powerful man from a different era. He does not care to be richer than 
his neighbour if the world around him provides him with magnificent roads, railways, 
telegraphs, hotels, personal safety and aspirin” [1].  
Since its discovery in 1899, aspirin has become the most popular drug worldwide. The 
clinical use of aspirin, initially restricted to a successful treatment of rheumatic diseases, 
has been revolutionized by the development of low-dose formulations for the treatment 
and the prevention of cardiovascular diseases (CVD). In patients affected by coronary 
artery and cerebrovascular disease, the chronic assumption of aspirin has been 
associated with a consistent and significant reduction of mortality and recurrence of major 
atherothrombotic events. In this population, the increase in bleeding turns out to be 
acceptable in the end [2-3]. On the other hand, the role of antithrombotic drugs in primary 
prevention, for patients without previous CVD, is still unclear, because of their low risk of 
developing atherothrombotic events at baseline. More recently, many randomized trials 
and meta-analyses have suggested a beneficial role of aspirin even in the setting of 
primary prevention of CVDs. 
Indeed, the favorable effects of a preventive therapy with aspirin are not likely to disappear 
when moving from the setting of secondary prevention to primary prevention in high-risk 
patients, as the CV risk develops as a continuum rather than following a switch on/off 
pattern.   
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Data from both experimental and observational studies have demonstrated that aspirin 
might play a role in preventing colorectal cancer (CRC) and other types of cancer. This 
possible additional beneficial effect is very appealing, and may therefore strengthen and 
broaden the indications of the treatment with aspirin in populations at average risk. 
Prospective and randomized studies are currently investigating the effect of aspirin for the 
prevention of both cancer and CVD [4-6].  
To assess the expected magnitude of the reduction of CV events with aspirin therapy, it is 
essential to estimate the baseline CV risk for everyone. For this purpose, the Framingham 
coronary heart disease (CHD) risk score [7], the American College of Cardiology/American 
Heart Association (AHA/ACC) Task Force risk equations [8] and the Systematic Coronary 
Risk Evaluation (SCORE) system, recommended by the European Society of Cardiology 
[9], are now widely used in clinical practice. The Framingham CHD risk score predicts the 
10-year risk of developing a coronary event (a composite of myocardial infarction-MI and 
coronary death), so that individuals are categorized as low (<10%), moderate (10% to 
20%), or high (>20%) risk. The SCORE system estimates the 10-year risk of a fatal 
atherosclerotic event: individuals should be considered at low risk with a SCORE <1%, at 
moderate risk with a SCORE >1% and <5%; at high risk with a SCORE >5% and <10%; 
and at very high risk with a SCORE 10%. [9] The combined risk of fatal and nonfatal CV 
events is three-fold higher than of fatal events alone. [9] 
Similarly, to assess the individual likelihood of CRC, several risk-prediction models have 
been designed. Freedman et al. have proposed a chart that estimates the chance of 
developing CRC given a specific age, risk-factor profile (including colonoscopy and 
adenoma history in the last 10 years, number of relatives with CRC, leisure and physical 
activity time, regular use of aspirin/NSAIDs, smoking, vegetable intake, body mass index, 
and, for white women aged ≥50 years, estrogen status within the last 2 years). [10] 
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In this view, the development of a composite or combined prediction model for CV and 
CRC risk may be extremely helpful and appealing, and it would allow the assessment of 
the global risk/benefit odd of aspirin therapy in primary prevention.  
Even before the scientific community will be able to assess the specific role of aspirin in 
primary prevention with conclusive results derived from ongoing trials, it appears 
reasonable to anticipate this recommendation in selected individuals at high CV risk, 
because this strategy might possibly contribute to avoid many CV events and their 
dangerous consequences for patients, national health services and national economies.  
 
Aspirin for the primary prevention of cardiovascular disease: PROS  
Since 1980s, 9 large-scale prospective randomized controlled trials (RCT) have analyzed 
the role of aspirin in primary prevention: the British Doctors’ Trial (BMD) [11], the Women’s 
Health Study (WHS) [12], the Primary Prevention Project (PPP) [13], the Physicians’ 
Health Study (PHS) [14], the Thrombosis Prevention Trial (TPT) [15], the Hypertension 
Optimal Treatment (HOT) study [16], the Japanese Primary Prevention of Atherosclerosis 
With Aspirin for Diabetes (JPAD) [17] trial, the Aspirin for Asymptomatic Atherosclerosis 
Trial (AAAT) [18] and the Prevention of Progression of Arterial Disease and Diabetes 
(POPADAD) trial [19], including altogether more than 100,000 participants [20], with a 1:1 
ratio between ASA and non on ASA patients. 
The Physicians’ Health Study (PHS) [14] enrolled men aged ≥40 years, randomized to 
aspirin 325 mg every other day or placebo. With regards to the secondary endpoint of 
myocardial infarction (MI), there was a 44% reduction in the group treated with aspirin 
versus placebo. Similar results were obtained in the Thrombosis Prevention Trial (TPT), 
which enrolled high-risk patients [15]. The Hypertension Optimal Treatment (HOT) trial 
[16], including almost 20,000 patients aged 50-80 years old and randomized to aspirin 75 
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mg or placebo, and the Primary Prevention Project (PPP) [13], including 4,495 individuals 
aged >65 years randomized to aspirin or placebo for three years, demonstrated a 
significant reduction of MIs (36% and 25% respectively) when taking aspirin.  
However, in the British Doctors Trial (BDT) [11], that enrolled about 5,000 healthy men 
aged <80 years old, randomized to aspirin 500 or 300 mg for six years, the investigators 
failed to report a reduction of MIs and CVD mortality.  
Individuals with a higher baseline CV risk have been enrolled in 3 recent RCTs. The 
Prevention of Progression of Arterial Disease and Diabetes (POPADAD) [19] trial 
randomized more than 1,000 individuals affected by type 1 or 2 diabetes mellitus and an 
ankle brachial index <0,99 to ASA 100 mg or placebo. It did not show any significant 
difference in CV endpoints between the two groups. On the other hand, in the Japanese 
Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial [17], which 
included about 2,000 diabetic patients randomized to aspirin 81 mg or placebo, the 
primary endpoint, a composite of CV and cerebrovascular fatal and nonfatal events, 
showed fewer events in the aspirin arm. In contrast, significant differences in the number 
of fatal and nonfatal coronary artery events, ischemic stroke and peripheral artery 
thrombotic events were not demonstrated in the Aspirin for Asymptomatic Atherosclerosis 
Trialists study (AAAT) [18], which included more than 3,000 patients with an ankle brachial 
index <0,95 randomized to aspirin 100 mg or placebo.  
Data on female subjects were obtained in the Women’s’ Health Study (WHS) [12], which 
enrolled more than 40,000 women >45 years old, did not show a significant reduction in 
the primary endpoint of MI, fatal and non-fatal, and death, CV or not. On the other hand, 
aspirin assumption was associated with a 22% reduction of ischemic stroke. Instead, 
currently data show a consistent benefit of aspirin in women aged >65 years, leading to a 
26% reduction of CV events and 30% of ischemic stroke. 
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Following the publication of these trials, new meta-analyses have revisited pooled data on 
the role of aspirin in CV prevention. The Anti-Thrombotic Trialists Collaboration has carried 
one of the most important one. [21] The endpoints were fatal and non-fatal MI, non-fatal 
hemorrhagic and ischemic stroke; all cause death and a composite of MI, stroke and 
atherotrombotic death. Reductions by aspirin were reported for MI and non-fatal stroke, 
especially ischemic ones, with an increase in bleeding events. No difference was reported 
in the number of CV deaths.  
A different meta-analysis of 10 trials, including 118,445 individuals aged 55-65 years, was 
carried out by the US Preventive Society Task Force (USPSTF) [22], and demonstrated a 
consistent efficacy of aspirin therapy in the prevention of nonfatal MI (relative risk [RR] 
0.83 [95% CI, 0.74 to 0.94]) and stroke (RR, 0.86 [CI, 0.76 to 0.98]), but not CV death (RR, 
0.94 [CI, 0.86 to 1.03]). A low-dose formulation <100 mg was administered in 8 studies; 
the follow-up lasted a mean of 3-10 years.  A significant reduction of all-cause mortality 
(RR, 0.94 [CI, 0.89 to 0.99]) was demonstrated with aspirin at any dose, not only with low 
dose therapy. [22] 
Special attention should be reserved to diabetic patients whose CV risk is 2-4 times 
greater than non-diabetic patients. [23-24-25] Univocal results about the efficacy of aspirin 
in primary prevention in diabetic patients are not yet available. Inconclusive data derive 
from three randomized trials that enrolled only diabetic individuals [17; 19; 26] and from six 
trials including a diabetic subgroup (1%-22% of cumulative number)  [11-16]. A non-
significant reduction of coronary artery (9%) and cerebrovascular (11%) events resulted 
from four meta-analyses. [23; 27-29] On the contrary, a recent meta-analysis of the 
USPSTF described a similar effect of aspirin therapy in patients either affected by type 2 
diabetes mellitus or not. [22] 
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THE WHS reported that in women aspirin did not seem to influence coronary artery 
events, CV and all-cause mortality. However, aspirin was associated with a 22% reduction 
of the number of transient ischemic attacks. [12] Currently available data show a 
consistent benefit of aspirin in women aged >65 years, leading to a 26% reduction of CV 
events and 30% of ischemic stroke. In this group of subjects, aspirin reduced risk of MI as 
well. The 2009 meta-analysis from the Antithrombotic Trialists' Collaboration showed that 
ASA plays a similar protective effect on CV in males and females. [21] 
 
Aspirin for the primary prevention of cardiovascular disease: CONS 
Therapy with aspirin is associated with an increased risk of major bleeding, especially 
gastrointestinal (GI) and intracranial bleeding events, defined as “a bleed requiring 
transfusion or resulting in death”. (30) Moreover, there is no evidence that enteric-coated 
aspirin may reduce gastric bleeding. [30-31-32] 
A meta-analysis of six placebo-controlled RCTs showed that treatment with aspirin was 
associated with an increase in the relative risk of hemorrhagic stroke of 32% [21]. The 
bleeding risk increases with concurrent anticoagulation or NSAID use, smoking, 
uncontrolled hypertension, male sex, older age, history of GI ulcers or upper GI pain, 
bleeding disorders, renal failure, severe liver disease and thrombocytopenia. [33-34] 
Therefore, the bleeding risk appears to be higher in individuals at higher CV risk, who 
might have the greatest benefit from aspirin therapy. In low-risk population treated with 
aspirin, 4 more bleeds per 1,000 persons have been calculated, versus 22 more bleeds 
per 1,000 persons in high-risk individuals. [7]  
 
Aspirin for the primary prevention of colorectal cancer 
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CVDs and cancer are the leading causes of mortality and morbidity worldwide, as they 
together account for almost 2/3 of global mortality. It is now well known that they both 
share many risk factors, such as cigarette smoking, high-calorie diet, alcohol abuse, a 
sedentary lifestyle, a low socio-economic status and environmental pollution. [35-42] 
Therefore, targeted interventions on lifestyle were effective, although not univocally, in 
preventing both diseases. [43-44] 
On the other hand, many studies, especially in animals, have shown that CV drugs such 
as ACE inhibitors and angiotensin receptor blockers [45-46], beta-blockers [47] and statins 
[48-49] may play a role in cancer prevention. It seems that ASA, through the irreversible 
inhibition of cyclooxygenase-1 (COX 1) (low dose) and COX-2 (high dose), may be able to 
inhibit specific pathways of carcinogenesis. Cohort studies have also shown a reduction in 
mortality from all causes and from cancer in patients with non-metastatic colorectal cancer 
who had started to regularly aspirin intake after diagnosis. [50-51] Some RCTs have also 
highlighted that aspirin decrease the recurrence of colorectal adenomas in patients 
undergoing endoscopic polypectomy. [52-53] 
These data are supported by large meta-analyses that [6-54-55] have demonstrated that 
aspirin, when assumed for more than 5 years at a daily dose of 75 to 300 mg, can reduce 
the incidence of CRC by 40% [56], 20 years-mortality (10.2% versus 11.1% in placebo 
groups) and the risk of metastasis after a latency period of 8-10 years. This benefit seems 
to increase further with duration of the treatment. [57] However, these results derive from 
post-hoc analysis of RCTs designed and conducted to evaluate CV outcomes. Moreover, 
the exclusion of the WHS and PHS, which previously failed to show the protective effect of 
aspirin on cancer genesis, should be considered. [58] Thus, recently, the 15 years’ follow-
up of the WHS showed a net benefit of alternate-day regimen with aspirin when 
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considering CV events, the development of cancer and gastrointestinal bleeding in women 
≥65 years. [59-60] 
Data on the benefit of aspirin in the prevention of different types of cancer such as prostate 
[61], breast [62], oesophagus [63], and head-and-neck [64] are much less robust. [65-67] 
As mentioned above, the effects of the aspirin in the prevention of CRC seem to achieve a 
significance after at least 5-10 years of therapy. [68-69] Therefore, we believe that the 
greatest benefit might be achieved by initiating treatment in patients aged between 40 and 
59 years. [70] However, more “ad hoc” studies will be required to clarify the effect of 
aspirin per different genders, age, race and genetics. It remains to be univocally determine 
the best dosage of aspirin to be used and its possible effects in the long term, about the 
duration of its beneficial effects after discontinuation of therapy.  
Looking at the evidence collected so far, now, the use of aspirin for primary prevention is 
not recommended in patients at intermediate risk for CRC (adults of 50-70 years with a 
family history, but in the absence of hereditary diseases, such as Lynch syndrome and 
familial adenomatous polyposis and inflammatory bowel disease). The American Cancer 
Society has not made recommendations for or against the administration of aspirin, while 
the American Gastroenterological Association recommend the use only in patients with 
high risk for CRC. [71] 
 
Recommendations of International Scientific Societies about the use of aspirin in 
primary prevention.  
Inappropriate and "off-label", often based on patients’ preference, prescription of aspirin for 
primary prevention is a usual finding in clinical practice, because there is not a clear and 
unambiguous indication on whom might benefit more from this treatment. [72] The Food 
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and Drug Administration has denied the indication of aspirin for the CV primary prevention 
in the USA. In Italy, on the other hand, personal choices of every patient often take over. 
Generally, the scientific community shares the belief that the decision to begin the therapy 
with aspirin for primary CV prevention, should be evaluated on an individualized basis, and 
be tailored on the CV risk profile and the risk of haemorrhage. The individual 
characteristics of patients, the expected benefits, the potential risks and preferences of 
subjects should be considered to characterize, as far as possible, the role of aspirin with a 
view for an integrated primary prevention (Figure 1). 
Per the latest guidelines of the European Society of Cardiology (ESC), ASA (or 
clopidogrel) is not recommended for individuals without CV or cerebrovascular disease 
because of the increase in the risk of bleeding (9). However, aspirin may be indicated for 
hypertensive patients with renal insufficiency or at high CV risk and should be considered 
in diabetes mellitus. [9] 
The American College of Chest Physicians guidelines [7], if aspirin, when taken for more 
than 10 years, might reduce mortality from CV causes regardless of the starting risk 
profile, suggest low-dose use in all subjects aged >50 years in the absence of 
contraindications. The American Heart Association and the American Stroke Association 
[73] recommend the use of low-dose aspirin in patients with a risk of CV events high 
enough to offset the potential adverse effects of the treatment, i.e., 6-10% in 10 years. 
The American Diabetes Association and the American Cardiology Collaboration [23] 
currently suggest aspirin for CV primary prevention for patients with diabetes mellitus and 
a CV risk >10% at 10 years (men >50 years old and women >60 years old with at least 
one more risk factor, as smoking, hypertension, dyslipidemia, albuminuria, family history of 
CVD), who are not at increased risk for bleeding (history of gastroduodenal ulcer, 
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gastrointestinal bleeding, use of medications which increase the risk of bleeding). aspirin is 
not recommended in males aged <50 years and women aged <60 years with low CV risk, 
because the risk of bleeding would exceed the potential benefits. Finally, aspirin could be 
considered in middle CV risk diabetic patients (young patients with at least one risk factor, 
elderly patients with no additional risk factors, patients with 5-10% risk of events in 10 
years). [23] 
The most recent recommendations have been issued by the USPSTF Guidelines. [22]. 
This document takes into account very accurately major thromboembolic risk factors (such 
as male gender, older age, race, dyslipidemia, hypertension, diabetes and cigarette 
smoking) and hemorrhagic risk factors (longer use of higher dosage of aspirin or other 
anti-inflammatory, history of ulcer disease or gastrointestinal disorders, blood coagulation 
disorders, renal insufficiency or severe hepatic, thrombocytopenia) when assessing the 
indication for therapy with aspirin. In addition, the analysis focuses on estimating the years 
of net life (DALYs) and the years of quality of life (QALYs) gained by administration of 
aspirin. 
The USPSTF recommends the initiation of therapy with low-dose aspirin (average 81 mg) 
for the prevention of CV events and CRC in adults aged 50-59 years with 10-year CV risk 
>10% and a life expectancy of 10 years, who are willing to take on a long-term treatment 
(at least for 10 years) and who do not feature increased bleeding risk (grade B 
recommendation, reasonable assurance of a net benefit). It is reasonable that, in these 
individuals, the benefit in the prevention for MI, stroke and CRC outweighs the risk 
associated with gastrointestinal and cerebral bleeding, and that the higher gain can be 
achieved in terms DALYs (219-463 in women, in men 333-605) and QALYs (621-833 in 
women, in men 588-834). 
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In subjects aged between 60 and 69 years old, aspirin is not recommended, as the 
increase in life expectancy and life quality seems to not overcome the increase in 
haemorrhagic risk and the potential benefits in the prevention of CRC would appear after 
at least 10 years of continuous intake. [74] The decision to start treatment should therefore 
be evaluated case-by-case based upon individual characteristics. Now, evidence about the 
indication to start the treatment with aspirin for individuals aged <50 and >70 years, at 
increased CV risk and average risk of CRC are scarce. In individuals aged <50 years, the 
potential benefits are likely to be lower, as only a small percentage of patients have a CV 
risk estimated at 10 years >10%. [22] For different reasons, in adults aged >70 years, 
even though not yet stated clearly, the benefits of therapy with aspirin in primary 
prevention could be substantial, because of the given high CV risk frequently related to 
older age. 
All these recommendations, often divergent, may be confusing in daily clinical practice. For 
this reason, a recent paper published by the European Society of Cardiology Working 
Group on Thrombosis [75] suggests to refer to a CV risk threshold above which the 
benefits of taking aspirin certainly outweighs the bleeding risks. This level has been 
identified as the 2% chance of major CV events/year, which corresponds to a CV risk 
assessed with the SCORE scale of 7-10% of death at 10 years. All subjects with a CV risk 
greater than or equal to that cut-off should consider treatment with aspirin. In subjects with 
CV risk between 1% and 2% the decision to start therapy with aspirin depends on the 
doctor's assessment of other comorbidities of the patient, especially regarding the risk of 
bleeding, and on the preferences of each patient. (Figure 2) 
In this regard, the search for additional indexes of vascular organ damage is crucial. 
Indeed, even though they are generally not included in clinical studies, they might 
conversely be informative indicators of susceptibility and prediction of atherothrombotic 
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events, such as documented atherosclerosis of the carotid-vertebral axis, peripheral 
vascular disease, the ankle-brachial index, calcium score assessed with CT, and atrial 
fibrillation as well. 
 
Clues from individualized integrated risk estimation to prospective studies 
The struggle to define the net clinical benefit of a therapy with aspirin in patients without 
pre-existing CV disease is therefore all about finding the best possible estimation of the 
risk of atherothrombotic events and bleeding. [76-78] The clinician plays a crucial role, 
he/she should recommend therapy with aspirin to patients at high atherothrombotic risk 
with a low risk of bleeding and vice versa. 
However, it must be stressed, that the analytical models proposed so far about the 
risk/benefit ratio usually have given the same importance to non-fatal ischemic events and 
bleeding events. Excluding the hemorrhagic stroke, which has often dramatic 
consequences in terms of disability and mortality, but only accounts for 1/5 of major 
bleedings [77], and major gastrointestinal bleedings, which are otherwise not frequent and 
usually easily manageable, probably many patients may still choose to accept a moderate 
increase in the bleeding risk consequent to treatment with aspirin in order to prevent CV 
and cerebrovascular ischemic events. According to the USPSTF, it is therefore crucial to 
take opinions and preferences of the informed patient into account. [22] 
In this context, the reduction in cancer incidence and mortality could be of great 
importance to extend the indication of treatment with aspirin. [78] A score for the 
calculation of an integrated CV and oncological benefit/risk would be highly desirable, and 
could be a crucial tool for the clinician while awaiting for prospective studies able to clarify 
the dual combined role for aspirin in preventing CV and neoplastic diseases further.  
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As mentioned earlier, prospective studies are currently undergoing to analyze the role of 
aspirin in primary prevention; these could help to address the lack of data at our 
knowledge today, and obviously may represent the best possible evidence to propose on 
not aspirin in primary prevention and drive future medical choices. However, they may 
provide a relatively short snapshot of 5-6 years, which is hard to translate to a strategy that 
may prevent CV or neoplastic events that may occur 10-30 years later. In addition, reliable 
conclusion of a sufficient number of prospective studies in heterogeneous populations may 
take a few more years to become available. 
The ACCEPT-D (Aspirin and Simvastatin Combination for Cardiovascular Events 
Prevention Trial in Diabetes) study [79] will evaluate benefits of the addition of low-dose 
aspirin therapy in diabetic patients already taking simvastatin. The primary composite 
endpoint includes death from CV causes, nonfatal Mi, nonfatal stroke and hospitalization 
for CV causes (acute coronary syndrome, transient ischemic attack, peripheral arterial 
disease). It is expected to enroll approximately 5170 patients and reach a total of 515 
events. Too little? Too specific? Too late? 
The purpose of the ASCEND (A Study of Cardiovascular Events iN Diabetes Study) [80] is 
to evaluate, in diabetic patients without previous atherothrombotic events, if therapy with 
100 mg of aspirin is able to significantly reduce the number of CV events compared to 
placebo and/or one gram of polyunsaturated omega-3 fatty acids. Adverse events, 
particularly the hemorrhagic ones, will be assessed. The primary composite endpoint will 
consist of death from CV causes (not hemorrhagic stroke), nonfatal MI, nonfatal stroke and 
transient ischemic attack. Again a very specific approach difficult to extend to the general 
population. 
The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) [81] is an international 
randomized, double-blind placebo study, which aims to evaluate the effectiveness and 
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safety of a therapy with 100 mg enteric coated aspirin in in primary prevention for patients 
with an estimated risk of CVD >15% at 10 years (male patients aged ≥50 years with 2-3 
and CV risk factors and female patients aged ≥60 years with 3 or more risk factors). The 
study will enroll about 12,000 patients, with an estimated duration of approximately five 
years, and reaching a total of 1488 events. The primary composite endpoint will be of 
death from CV causes, nonfatal MI and nonfatal stroke. This appears a more promising 
and meaningful approach. 
The ASPREE trial (Aspirin in Reducing Events in the Elderly) [82] will examine the benefits 
of aspirin in the reduction of MI, stroke, dementia and some types of cancer in subjects 
older than 65 years (70 years for Caucasian) over the potential risks, particularly bleeding. 
The study will also determine the amount of years of life free from disability. The primary 
endpoint will consist of all-cause death, dementia and persistent physical disabilities. The 
secondary endpoint is a composed of fatal and non-fatal CV and cerebrovascular events, 
hospitalization for heart failure, fatal and nonfatal cancers, major bleeding events, 
depression. 
Altogether these studies may add important information on the appropriateness of using 
aspirin in primary prevention. However, by the time being, they will be all completed, the 
population candidate for ASA in primary prevention, particularly in the middle age (50-65 
years) may be left at risk, unless a programmatic clinical approach is considered in the 
meanwhile. 
The purpose of the present document is to help physicians in unraveling a complex and 
controversial prevention topic. This will most likely represent in the coming years one of 
the main themes of CV prevention. 
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Figure legends 
Figure 1. Clinical evaluation of risk profile for prescription of aspirin in primary prevention 
to be taken into account on an individualized basis. 
 
Figure 2. Suggested algorithm to be adopted in everyday clinical practice to prescribe 
aspirin in primary prevention. (modified from Ref 77) 
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